<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27635">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746952</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-68587-002</org_study_id>
    <nct_id>NCT02746952</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study to Evaluate the Safety, Tolerability and Biological Activity of a Single Dose of UCART19 in Patients With Relapsed / Refractory (R/R) B-cell Acute Lymphoblastic Leukaemia (ALL) and Chronic Lymphocytic Leukaemia (CLL)</brief_title>
  <acronym>CALM</acronym>
  <official_title>Phase I, Open Label, Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Biological Activity of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL) or Chronic Lymphocytic Leukaemia (CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of several doses of
      UCART19 in patient with relapsed / refractory (R/R) acute lymphoblastic leukaemia (ALL) or
      chronic lymphocytic leukaemia (CLL)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v4.0 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-leukemic activity of UCART19</measure>
    <time_frame>At day 28</time_frame>
    <description>The biological active dose will be the dose leading to, at least, 66% patients with objective responses in the cohort, either in ALL or CLL patients or both, at Day 28.
For ALL: an objective response is defined as: (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014) or (3) a negative minimal residual disease (MRD &lt; 10^-4 post treatment).
For CLL: an objective response is defined as: (1) a complete response or (2) a partial response (based on CLL guidelines, (Hallek, 2008)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD) evaluation</measure>
    <time_frame>At day 28</time_frame>
    <description>Assessed by multiparametric flow cytometry or qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>At day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Acute Lymphoblastic Leukaemia</condition>
  <condition>Chronic Lymphocytic Leukaemia</condition>
  <arm_group>
    <arm_group_label>UCART19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>UCART19</intervention_name>
    <arm_group_label>UCART19</arm_group_label>
    <other_name>S68587</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participant

          -  Age ≥ 16 years

          -  Patient with relapsed or refractory CD19 positive B-acute lymphoblastic leukaemia
             (B-ALL) or chronic lymphocytic leukaemia

          -  Estimated life expectancy ≥ 12 weeks (according to investigator's judgement)

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

        Exclusion Criteria:

          -  Previous treatment with investigational gene or cell therapy medicine products

          -  CD19 negative B-cell leukaemia

          -  Richter's syndrome

          -  Burkitt cell acute leukaemia

          -  Previous chemotherapy including biologic/targeted therapy or immunological agents
             (including blinatumomab) within 3 weeks (nitrosoureas within 6 weeks) before
             Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reuben Benjamin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College Hospital NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>IRIS</last_name>
    <email>clinicaltrials@servier.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Reuben, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Benjamin Reuben, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 10, 2016</lastchanged_date>
  <firstreceived_date>March 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
